DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Emily Field - 2 Stocks - 1 Rahul Ghosh - 1 Rowe Price - 1 TRP's Ghosh - 1 Eli Lilly's - 1 Ghosh - 1
Top related locs:
Danish U.S Novo
Top related orgs:
Barclays - 3 Novo Nordisk - 2 European Pharmaceutical Research - 2 Nordisk - 1 CNBC Pro - 1 U.S . Food - 1 Administration - 1 pharma - 1

Search resuls for: "European Pharmaceutical Research"


3 mentions found


☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
  + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com   time to read: +4 min
It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.
Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo
☆ Wegovy slashes risk of serious heart events: What this means for patients and insurers
  + stars: | 2023-11-13 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWegovy slashes risk of serious heart events: What this means for patients and insurersEmily Field, head of European Pharmaceutical Research at Barclays, joins 'Squawk Box' to discuss a new study that suggests that the weight-loss drug Wegovy reduces the risks of heart attacks, what these results mean for patients and insurers, and more.
Persons: Emily Field Organizations: European Pharmaceutical Research, Barclays
☆ Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug race
  + stars: | 2023-08-10 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBarclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug raceEmily Field, Head of European Pharmaceutical Research at Barclays, discusses Novo Nordisk, Eli Lilly, and competition in the weight-loss/obesity drug space.
Persons: Eli Lilly, Emily Field Organizations: Barclays, Novo Nordisk, European Pharmaceutical Research
0 next >>
Total: 3